글로벌 연구동향
방사선종양학
- 2023년 03월호
[Medicine (Baltimore) .] Modulated electrohyperthermia in locally advanced cervical cancer: Results of an observational study of 95 patients
전북대병원 / 이선영, 조동휴*
- 출처
- Medicine (Baltimore) .
- 등재일
- 2023 Jan 20
- 저널이슈번호
- 102(3):e32727.
- 내용
Abstract
Most federation of gynecology and obstetrics stage II or higher locally advanced cervical cancer (LACC) patients are treated with concurrent chemoradiotherapy (CCRT); however, recurrence is high, and the prognosis is poor. In this observational retrospective study, data from LACC patients treated with CCRT alone or combined with modulated electrohyperthermia (mEHT) were collected from 2011 to 2018. Ninety-five LACC patients, including 53 (%) treated with CCRT alone and 42 (%) treated with CCRT + mEHT, were enrolled. The complete remission rate significantly increased with CCRT + mEHT compared with CCRT alone among LACC cases with lymph node metastasis (45% vs 71%, P = .0377). Additionally, at the last follow-up point, the no-evidence-of-disease rate significantly improved with CCRT + mEHT compared with CCRT (58% vs 82%, P = .0315). Disease-free survival increased in the CCRT + mEHT group with lymph node metastasis (P = .04). The addition of mEHT to CCRT led to a better therapeutic response in LACC with regional lymph node metastasis without severe complications.Affiliations
Sun Young Lee 1 2, Dong Hyun Lee 3, Dong-Hyu Cho 2 3
1Department of Radiation Oncology, Jeonbuk National University Hospital, Jeonju, Republic of Korea.
2Research Institute of Clinical Medicine of Jeonbuk National University-Biomedical Research Institute of Jeonbuk National University Hospital, Jeonju, Republic of Korea.
3Department of Obstetrics and Gynecology, Jeonbuk National University Hospital, Jeonju, Republic of Korea.
- 덧글달기
- 이전글 [Jpn J Clin Oncol .] Patterns of regional recurrence according to molecular subtype in patients with pN2 breast cancer treated with limited field regional irradiation
- 다음글 [Breast Care (Basel) .] Treatment Outcomes according to the EndoPredict Score in ER-Positive, HER2-Negative Early Breast Cancer